British Journal of Cancer · 2003 · 32 citations · 31 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyInnate ImmunityCancer ImmunotherapyCell-mediated ImmunityDendritic Cell BiologyImmunotherapy For Genitourinary CancersImmunotherapy For Urologic CancersToll-like ReceptorsAntigen-specific Immune PrimingAntigen-specific T Cell ResponsesDendritic Cell-mediated Antigen PresentationT Helper CellsT-cell Mediated Immune ResponseTh1 Immune ResponseTh1 ResponsesTh2 Immune Response
Intravesical bacillus Calmette-Guerin (BCG) is a treatment for transitional cell carcinoma (TCC) and carcinoma in situ (cis) of the urinary bladder, but some patients remain refractory. The mechanism of cancer clearance is not known, but T cells are thought to play a contributory role. Tissue dendritic cells (DCs) are known to initiate antigen-specific immune responses following activation of receptors, which recognise molecular patterns on the surface of microorganisms. A family of these receptors, the toll-like receptors (TLRs), are also crucial for activating DC to produce cytokines that polarise the T-cell response towards a T helper (Th)1 or Th2 phenotype. This study compared the potential of intact BCG to activate DC with that of the defined TLR4 ligand lipopolysaccharide (LPS) and the TLR9 ligand CpG-oligonucleotide. It was found that all three stimuli efficiently activated normal DC, but cells expressing a mutant TLR4 responded poorly to stimulation with LPS. Importantly, stimulation with BCG induced both IL-12 and IL-10, suggesting subsequent development of a poorly focused T-cell immune response containing both Th1 and Th2 immune function. By contrast, LPS- and CpG-oligonucleotides induced only IL-12, indicating the potential to produce a Th1 response, which is likely to clear cancer most efficiently. Given the toxicity of LPS, our data suggest that CpG-oligonucleotides may be beneficial for intravesical therapy of bladder cancer.
31
Endotoxin-tolerant Mice Have Mutations in Toll-like Receptor 4 (<i>Tlr4</i>)
Salman T. Qureshi, Line Larivière, Gary Leveque et al. · The Journal of Experimental Medicine · 1999 · 1.5K citations · Full text
Life Sciences, Genetics, Immunology +17